resTORbio is developing novel therapies to improve immune function in the elderly.
resTORbio, which is developing novel therapies to improve immune function in the elderly, announced terms for its IPO on Tuesday.
The Boston, MA-based company plans to raise $85 million by offering 5.7 million shares at a price range of $14 to $16. Insiders intend to purchase $35 million (41% of deal size) worth of shares in the offering. At the midpoint of the proposed range, resTORbio would command a fully diluted market value of $410 million.
